{
    "nctId": "NCT01045421",
    "briefTitle": "Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies",
    "officialTitle": "A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 273,
    "primaryOutcomeMeasure": "Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nEach patient must meet all of the following inclusion criteria to be enrolled in the study:\n\n* 18 years or older\n* Histologically or cytologically confirmed metastatic and/or advanced solid tumor (Phase 1 only)\n* Phase 2 requires Non-small cell lung cancer (NSCLC); Small-cell lung cancer; Breast adenocarcinoma (female patients only); Squamous cell cancer of the head and neck (HNSCC); or Gastroesophageal adenocarcinoma\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse\n* Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse\n* Voluntary written consent\n* Wiling to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures\n* Measurable disease (Phase 2 only)\n\nExclusion Criteria:\n\nPatients meeting any of the following exclusion criteria are not to be enrolled in the study:\n\n* Female patients who are pregnant or lactating\n* Serious medical or psychiatric illness that could interfere with protocol completion\n* Receipt of more than 2 previous cytotoxic chemotherapeutic regimens (4 previous regimens for breast cancer). There is no limit on the number of prior noncytotoxic therapies\n* Prior treatment with Aurora A-targeted agents, including MLN8237\n* Prior treatment with high-dose chemotherapy\n* Prior allogeneic bone marrow or other organ transplant\n* Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of MLN8237\n* Symptomatic brain metastasis\n* Radiotherapy to greater than 25% of bone marrow\n* Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected\n* Myocardial infarction within 6 months of enrollment\n* Uncontrolled cardiovascular condition\n* Major surgery within 14 days of first dose of MLN8237\n* Active infection requiring systemic therapy, or other serious infection\n* Inability to swallow oral medication\n* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C\n* Patients requiring full systemic anticoagulation\n* History of uncontrolled sleep apnea syndrome\n* Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}